+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05076760

Phase I Study of MEM-288 Oncolytic Virus Alone and With Standard Therapies for Advanced Solid Tumors

Led by Memgen, Inc. · Updated on 2026-06-11

40

Participants Needed

2

Research Sites

252 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MEM-288, an oncolytic adenovirus therapy, alone and in combination with standard treatments in patients with advanced solid tumors, including various types of cancer such as non-small cell lung cancer NSCLC, melanoma, and pancreatic cancer. This Phase I trial aims to determine the safety, maximum tolerated dose, recommended phase 2 dose, and preliminary effectiveness of MEM-288. The study rationale is based on MEM-288s ability to replicate in cancer cells, cause tumor cell lysis, and stimulate an immune response through its encoded immune agonists. The trial has several parts Part 1A tested MEM-288 monotherapy in escalating doses via intratumoral injections every three weeks, while Parts 1B and 1C focus on MEM-288 combined with nivolumab or docetaxel, respectively, in patients with advanced NSCLC. Dosing involves intratumoral injections of MEM-288 every three weeks, with up to six doses planned. Nivolumab is given intravenously every three weeks with optional maintenance, and docetaxel is administered intravenously every three weeks as standard care combined with MEM-288. During the study, participants undergo injections directly into accessible tumors and receive intravenous infusions as appropriate. Researchers monitor safety and tolerability through adverse event tracking and assess efficacy using measures such as overall response rate, disease control rate, progression-free survival, and overall survival. Participants may be followed for up to five years to evaluate long-term outcomes, with study visits and procedures scheduled accordingly to support these assessments.

CONDITIONS

Brief Title

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Research Team

C

Chairman, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here